FolioStart free

Public Health · Literature

Research papers on HPV vaccine and cancer

Recent and highly-cited academic work on hpv vaccine and cancer, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →

  1. Global cancer statistics

    Ahmedin Jemal, Freddie Bray, Jacques Ferlay, et al. · 2011 · CA A Cancer Journal for Clinicians · 55,073 citations

    The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in male

  2. Cancer statistics, 2019

    Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · 2019 · CA A Cancer Journal for Clinicians · 21,002 citations

    Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the National Center for Health Statistics. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (200

  3. Cancer Statistics, 2021

    Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs, et al. · 2021 · CA A Cancer Journal for Clinicians · 17,442 citations

    Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its p

  4. Cancer statistics, 2023

    Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle, et al. · 2023 · CA A Cancer Journal for Clinicians · 16,769 citations

    Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lu

  5. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

    Núbia Muñóz, F. Xavier Bosch, Sílvia de Sanjosé, et al. · 2003 · New England Journal of Medicine · 6,302 citations

    BACKGROUND: Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but the risk associated with the various HPV types has not been adequately assessed. METHODS: We pooled data from 11 case-control studies from nine countries involving 1918 women with histologically confirmed squamous-cell cervical cancer and 1928 control women. A common protocol and questionnaire were used. Information on risk factors was obtained by personal interviews, and cervical cells were collected for detection of HPV DNA and typing in a central laboratory by polymerase-chain-reaction-based assays (with MY09/MY11 and GP5+/6+ primers). RESULTS: HPV DNA was detected in 1739 of the 1918 patients

  6. Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

    Peter Pushko, Paul Pumpens, Elmars Grens · 2013 · Intervirology · 5,972 citations

    On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers and genital warts). The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of females at age 11 or 12 years and catch-up vaccination for females aged 13 through 26 years. On October 21, 2009, ACIP provided gu

  7. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

    F. Xavier Bosch, M. Michele Manos, N. Munoz, et al. · 1995 · JNCI Journal of the National Cancer Institute · 3,434 citations

    BACKGROUND: Epidemiologic studies have shown that the association of genital human papillomavirus (HPV) with cervical cancer is strong, independent of other risk factors, and consistent in several countries. There are more than 20 different cancer-associated HPV types, but little is known about their geographic variation. PURPOSE: Our aim was to determine whether the association between HPV infection and cervical cancer is consistent worldwide and to investigate geographic variation in the distribution of HPV types. METHODS: More than 1000 specimens from sequential patients with invasive cervical cancer were collected and stored frozen at 32 hospitals in 22 countries. Slides from all patient

  9. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions

    The FUTURE II Study Group · 2007 · New England Journal of Medicine · 2,063 citations

    BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. METHODS: In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group

  10. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.

    Z. Zou, C. Fairley, J. Ong, et al. · 2020 · The Lancet. Global health · 147 citations

    BACKGROUND Coinciding with the release of the first Chinese domestic human papillomavirus (HPV) vaccine Cecolin in 2019, and the substantial advancements in cervical cancer screening technology, we aimed to evaluate the cost-effectiveness of the combined strategies of cervical cancer screening programmes and universal vaccination of girls (aged 9-14 years) with Cecolin in China. METHODS We did a cost-effectiveness analysis in China, in which we developed a Markov model of cervical cancer to evaluate the incremental cost-effectiveness ratios of 61 intervention strategies, including a combination of various screening methods at different frequencies with and without vaccination, and also vac

  13. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool

    R. Hutubessy, A. Levin, Susan A. Wang, et al. · 2012 · BMC Medicine · 62 citations

    BackgroundThe purpose, methods, data sources and assumptions behind the World Health Organization (WHO) Cervical Cancer Prevention and Control Costing (C4P) tool that was developed to assist low- and middle-income countries (LMICs) with planning and costing their nationwide human papillomavirus (HPV) vaccination program are presented. Tanzania is presented as a case study where the WHO C4P tool was used to cost and plan the roll-out of HPV vaccines nationwide as part of the national comprehensive cervical cancer prevention and control strategy.MethodsThe WHO C4P tool focuses on estimating the incremental costs to the health system of vaccinating adolescent girls through school-, health facil

  14. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

    S. Skinner, D. Apter, N. D. de Carvalho, et al. · 2016 · Expert Review of Vaccines · 53 citations

    ABSTRACT Vaccines are available against human papillomavirus (HPV), the causal agent of cervical and other cancers. Efficacy data from the HPV-16/18 AS04-adjuvanted vaccine clinical trial program were reviewed. Six randomized, controlled phase II/III trials evaluating cervical endpoints enrolled women from diverse populations and geographical locations. The program analyzed extensively the cohorts most relevant from a public health perspective: the total vaccinated cohort (TVC), approximating a general population including those with existing or previous HPV infection, and TVC-naïve, approximating a population of young women before sexual debut. Results show that the vaccine reduces HPV-16/1

  17. A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer

    Pranav Pathak, S. Pajai, Himanshi Kesharwani · 2022 · Cureus · 38 citations

    The main risk factor for invasive cervical carcinoma is persistent infection by the high-risk human papillomavirus (HPV). HPV is the most prevalent sexually transmitted infection (STI) and has been linked to 15 different cancers. Cervical cancer is one of the most frequent cancers among women, particularly in resource-limited countries. Cervical cancer is an HPV disease with the highest worldwide burden in resource-limited nations. With improved medical care and nationwide screening programmes, the mortality rate from cervical cancer has decreased in the past 40 years. Many developing nations have been shown to have inadequate knowledge and health-seeking practices, making proper awareness a

  18. Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China

    Fengzhi Zhang, Manman Li, Xiaoxue Li, et al. · 2022 · BMC Public Health · 36 citations

    Cervical cancer is the fourth most common cancer in women. Up to 99% of cervical cancer cases are associated with high-risk human papillomavirus (HPV). Sexual behavior is a direct risk factor for HPV infection, and sexually active college students, therefore, receive attention for HPV vaccination. At present, most Chinese studies lack of in-depth research on influencing factors, and are limited to cervical cancer, HPV, or HPV vaccine, without comprehensive consideration. This study investigated Chinese college students’ cervical cancer prevention and treatment knowledge level, and explored the influencing factors, and understood their willingness to receive HPV vaccination. The findings of t

  19. Knowledge regarding cervical cancer and HPV vaccine among medical students: A cross-sectional study

    Jyoti Singh, S. Baliga · 2021 · Clinical Epidemiology and Global Health · 36 citations

    Abstract Background Healthcare workers, especially the young medical students, can play a significant role in providing the recommendations to prevent or manage cervical cancer (CC) caused by human papilloma virus (HPV). However, it is often observed that the awareness about the knowledge of CC and HPV is limited in the medical students, who are part of the front-line support for managing the patients. Objective To evaluate the knowledge, attitude, and acceptance of CC and HPV vaccine among medical students. Method ology: In this cross-sectional study, 297 medical students of the age group >18 years were included. Their knowledge regarding cervical cancer (risk factors, screening and prevent

  20. Health Belief Model on the Factors Associated with the Use of HPV Vaccine for the Prevention of Cervical Cancer Among Women in Kediri, East Java

    R. Nugrahani, U. R. Budihastuti, Eti Poncorini Pamungakasari · 2017 · 33 citations

    Background : Cervical cancer is a deadly disease with high incidence rates in the world and in Indonesia. In Kediri, East Java, there were 33 women who had cervical cancer in 2016, 3 of them died. Cervical cancer is caused by type 16 and type 18 Human Papilloma Viruses (HPV).  This disease can be prevented by the application of HPV vaccine. This study aimed to examine factors associated with the use of HPV vaccine for the prevention of cervical cancer among women in Kediri, East Java, using health belief model (HBM). Subje cts and Met h od: This study was an analytic observational with case control design. It was conducted in Kediri, East Java, from February 10 to March 10, 2017. A sample o

  21. Challenges in Cervical Cancer Prevention: Real-World Scenario in India

    Satinderbir Kaur, L. Sharma, V. Mishra, et al. · 2023 · South Asian Journal of Cancer · 30 citations

    Abstract Satinder Kaur In spite of global falling trends, cervical cancer remains a major healthcare challenge for India, South Asia Association for Regional Cooperation region, and other low- and middle-income countries. Our survey was to document the real-world challenges that still exist in India. A total of 316 eligible and complete responses to the 21 questions were analyzed. Screening of mothers and vaccinating their daughters was considered as the most important strategy to prevent cervical cancer by 65.8% (208/316). Screening was offered to all asymptomatic eligible females by 79% (250/316). Improvement in screening rates requires promoting the national program (67.7%; 214/316), stre

  23. Empowering Women’s Health: Insights Into HPV Vaccination and the Prevention of Invasive Cervical Cancer

    Sachin Rathod, Jyotsna Potdar, Aishwarya Gupta, et al. · 2023 · Cureus · 24 citations

    This review article provides a comprehensive analysis of the role of human papillomavirus (HPV) vaccination in empowering women's health by preventing invasive cervical cancer. Cervical cancer remains a significant global health concern, with HPV infection identified as a primary causative factor. The review synthesizes current research findings, epidemiological data, and clinical outcomes to offer a nuanced understanding of the impact of HPV vaccination on cervical cancer prevention. The article explores the biology of HPV, emphasizing its association with cervical carcinogenesis and the development of precancerous lesions. It delves into the epidemiology of HPV infection, highlighting the

  24. Beliefs About HPV Vaccine’s Success at Cervical Cancer Prevention Among Adult US Women

    Joël Fokom Domgue, O. Chido-Amajuoyi, Robert Yu, et al. · 2019 · JNCI Cancer Spectrum · 19 citations

    Abstract Background Beliefs are known to be a key determinant in vaccines’ uptake. However, little is known about beliefs surrounding the success of the human papillomavirus (HPV) vaccine in preventing cervical cancer in the United States. Methods Data from the Health Information National Trends Survey 5 Cycle 1 (2017) were analyzed for 1851 female respondents aged 18 years and older. Weighted multinomial logistic regression was employed to determine predictors of beliefs in the success of the HPV vaccine in preventing cervical cancer. Results Overall, 29.8% of women believed that HPV vaccine is successful in preventing cervical cancer, 6.6% believed it is not successful, and 63.6% did not k

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →